ISPE Hits Recruitment Milestone for Quality Metrics Pilot Program - Pharmaceutical Technology

Latest Issue
PharmTech

Latest Issue
PharmTech Europe

ISPE Hits Recruitment Milestone for Quality Metrics Pilot Program


ISPE announced on Aug. 8 that its Quality Metrics Pilot Program has achieved a milestone with confirmation of 12 companies and 32 sites participating, even as recruitment continues. The participating companies represent generic, innovator, over-the-counter, contract manufacturing, and analytical businesses with solid dosage, sterile, drug substance, small and large molecule technologies.

At a meeting of the Quality Metrics team during the week of July 14, arrangements were made to establish multiple forums that will enable participating companies to influence the outcome of the Pilot Program. There are also opportunities for participants to develop insights into the quality performance of their sites, ISPE reports. Participating companies will provide up to 12 months of historic and a limited amount (3 months) of current data as Wave 1 of the Program.

A planned Wave 2 will expand the number of participants; assess a potentially adjusted metric set based on learning from Wave 1 and status of any regulatory announcements; include input from sub teams working on Leading Quality Indicators/Quality Culture and Process Capability; be based more on current data collection and analysis; and consider cooperating with other groups and associations.

The objective of the Pilot Program is to provide experiential input on the development and use of quality metrics for the benefit of both industry and regulators.

Source: ISPE

ADVERTISEMENT

blog comments powered by Disqus
LCGC E-mail Newsletters

Subscribe: Click to learn more about the newsletter
| Weekly
| Monthly
|Monthly
| Weekly

Survey
What role should the US government play in the current Ebola outbreak?
Finance development of drugs to treat/prevent disease.
Oversee medical treatment of patients in the US.
Provide treatment for patients globally.
All of the above.
No government involvement in patient treatment or drug development.
Finance development of drugs to treat/prevent disease.
27%
Oversee medical treatment of patients in the US.
12%
Provide treatment for patients globally.
8%
All of the above.
46%
No government involvement in patient treatment or drug development.
7%
Jim Miller Outsourcing Outlook Jim MillerCMO Industry Thins Out
Cynthia Challener, PhD Ingredients Insider Cynthia ChallenerFluorination Remains Key Challenge in API Synthesis
Marilyn E. Morris Guest EditorialMarilyn E. MorrisBolstering Graduate Education and Research Programs
Jill Wechsler Regulatory Watch Jill Wechsler Biopharma Manufacturers Respond to Ebola Crisis
Sean Milmo European Regulatory WatchSean MilmoHarmonizing Marketing Approval of Generic Drugs in Europe
Seven Steps to Solving Tabletting and Tooling ProblemsStep 1: Clean
Legislators Urge Added Incentives for Ebola Drug Development
FDA Reorganization to Promote Drug Quality
FDA Readies Quality Metrics Measures
New FDA Team to Spur Modern Drug Manufacturing

Click here